# Linagliptin

## Trajenta 5mg

| TAH Drug Code      | [OTRAJ](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OTRAJ)                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise as monotherapy or in combination with other antidiabetic agents.                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | 5 mg once daily.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to linagliptin or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | >10%: Endocrine & metabolic: Hypoglycemia (combined with metformin/sulfonylurea [15%], metformin [<1%], pioglitazone [<1%]; monotherapy [<1%]) Central nervous system: Headache (6%) Endocrine & metabolic: Hyperuricemia (3%), lipids increased (3%), triglycerides increased (2%), weight gain (2%) Neuromuscular & skeletal: Arthralgia (6%), back pain (6%) Respiratory: Nasopharyngitis (6%), cough (2%) <1% (Limited to important or life-threatening): Angioedema, hypersensitivity, pancreatitis |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| More Info          | [UpToDate](https://www.uptodate.com/contents/linagliptin-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                               |

